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ABSTRACT
Objectives: Agitation is common and problematic in care home residents with dementia. This
study investigated the (cost)effectiveness of Dementia Care MappingTM (DCM) for reducing agita-
tion in this population.
Method: Pragmatic, cluster randomised controlled trial with cost-effectiveness analysis in 50 care
homes, follow-up at 6 and 16 months and stratified randomisation to intervention (n¼ 31) and
control (n¼ 19). Residents with dementia were recruited at baseline (n¼ 726) and 16 months
(n¼ 261). Clusters were not blinded to allocation. Three DCM cycles were scheduled, delivered by
two trained staff per home. Cycle one was supported by an external DCM expert. Agitation
(Cohen-Mansfield Agitation Inventory (CMAI)) at 16 months was the primary outcome.
Results: DCM was not superior to control on any outcomes (cross-sectional sample n¼ 675: 287
control, 388 intervention). The adjusted mean CMAI score difference was –2.11 points (95% CI
–4.66 to 0.44, p¼ 0.104, adjusted ICC control ¼ 0, intervention 0.001). Sensitivity analyses sup-
ported the primary analysis. Incremental cost per unit improvement in CMAI and QALYs (interven-
tion vs control) on closed-cohort baseline recruited sample (n¼ 726, 418 intervention, 308 control)
was £289 and £60,627 respectively. Loss to follow-up at 16 months in the original cohort was 312/
726 (430%) mainly (872%) due to deaths. Intervention dose was low with only a quarter of
homes completing more than one DCM cycle.
Conclusion: No benefits of DCM were evidenced. Low intervention dose indicates standard care
homes may be insufficiently resourced to implement DCM. Alternative models of implementation,
or other approaches to reducing agitation should be considered.
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Introduction
Around 80% of care home residents have dementia
(Alzheimer’s Society, 2013). Agitation is particularly com-
mon and clinically challenging, in this group, causing dis-
tress for the person and other residents, but is not an
inevitable consequence of dementia, often being a
response to unmet needs and psychological distress.
Caring for people living with dementia who experience agi-
tation is also time consuming and complex (Livingston
et al., 2017). Thus, interventions to support care home staff
to reduce agitation may produce considerable benefits.
The limited efficacy and high risks of traditional pharmaco-
logical approaches to management of agitation (All-Party
Parliamentary Group on Dementia, 2008; NICE, 2018) mean
psychosocial responses are urgently required. Person-cen-
tred care (PCC) is a best practice psychosocial intervention
for addressing unmet needs in people with dementia, dem-
onstrated to be effective in reducing the incidence of agi-
tation and improving quality of life of care home residents
(Livingston, Kelly, et al., 2014; Livingston et al., 2017; NICE,
2018). However, training staff in PCC alone is unlikely to
support sustained implementation (Chenoweth, Stein-
Parbury, Lapkin, Wang, & Williams, 2019; Fossey et al.,
2019). Therefore, methods to support care home staff to
effectively embed and sustain PCC in practice are needed.
Dementia Care Mapping
Dementia Care MappingTM (DCM) (Bradford Dementia
Group, 2005) is an established, observational tool, set
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within a practice development cycle, used widely in care
home settings (Barbosa, Lord, Blighe, & Mountain, 2017) as
a whole home quality improvement intervention, to sup-
port the embedding of PCC in practice. It has been identi-
fied as a potentially effective method for reducing
agitation in people with dementia in care home settings
(Livingston, Kelly, et al., 2014). DCM places a focus on
understanding the psychosocial factors, including care
practices that may lead to unmet needs and their expres-
sion through behaviours such as agitation and can be used
to develop individualised care plans and address broader
care home practices (Barbosa et al., 2017). A logic model
for DCM is published elsewhere (Surr, Shoesmith,
et al., 2019).
However, robust evidence around its effectiveness and
cost-effectiveness is limited and varied. Benefits of DCM for
residents (reductions in resident agitation, depression, anx-
iety, neuropsychiatric symptoms, psychosis and falls, and
improvements in quality of life) and staff (communication
and connectedness, burnout) have been found in pilot
studies (Chenoweth & Jeon, 2007; Kuiper, Dijkstra, Tuinstra,
& Groothoff, 2009) and explanatory randomised controlled
trials (RCTs) (Chenoweth et al., 2009; Jeon et al., 2012;
Rokstad et al., 2013). However, an RCT (van de Ven et al.,
2013) and a quasi-experimental pragmatic controlled trial
(Dichter et al., 2015) found no significant benefits for DCM
over control for resident outcomes, although staff reactions
towards people living with dementia were improved. Cost-
effectiveness was investigated in two RCTs with DCM not
cost effective in one (Chenoweth et al., 2009) and cost-neu-
tral in the other (van de Ven et al., 2014).
Limitations of the explanatory RCTs to date include
implementation of only two DCM cycles and short follow-
up periods (10–12months), potentially reducing the oppor-
tunity to realise positive changes, which may take time to
implement and effect resident outcomes. This also limits
the period over which intervention sustainability can be
monitored. Additionally, explanatory trial designs, while
supporting understanding of intervention efficacy, do so
under controlled, optimal conditions, often using specially
selected sites and participants (Ford & Norrie, 2016), and
with smaller samples, meaning the findings do not always
translate into real-world practice. Inapplicability of trial
findings to clinical practice, is a frequent criticism aimed at
trials, by clinicians (Treweek & Zwarenstein, 2009).
Pragmatic/effectiveness trials assess the benefit of interven-
tions in ‘real world’ settings with a sample that is represen-
tative of the heterogenous population under study,
permitting generalisability of the results to the wider popu-
lation. They include the potential impact of external mod-
erating factors that may impact intervention benefits in
real-world situations (Singal, Higgins, & Waljee, 2014). As
such they produce evidence of practical importance regard-
ing whether particular interventions are accessible and rele-
vant/applicable to the majority of potential beneficiaries
(Tosh, Soares-Weiser, & Adams, 2011). Given the promising
results of DCM for resident and staff outcomes in explana-
tory trials, in order to expand this to its applications in
real-world situations, this trial aimed to conduct a timely
definitive, pragmatic effectiveness trial adequately powered
for generalisability and using methods aligned to routine
practice (Roland & Torgerson, 1998). This article reports the
results of this trial.
Aims
The DCM EPIC cluster RCT aimed to evaluate the clinical
and cost-effectiveness of DCM alongside usual care (inter-
vention), compared to usual care alone (control), for people
living with dementia in care homes in the UK. The primary
outcome was whether DCM reduced agitation at 16
months. Secondary outcomes included whether DCM
reduced other behaviours staff may find difficult to sup-
port (e.g. apathy, anxiety, depression), improved quality
of life, reduced the use of antipsychotic and other psy-
chotropic medications and improved the quality of staff/
resident interactions (e.g. more person-centred and less
task focussed).
Research design and methods
Design
Trial design and procedures are reported in the original
(Surr, Walwyn, et al., 2016) and revised (Surr, Ballard, et al.,
2016) protocols. This pragmatic, multi-centre, cluster RCT
recruited residential and nursing homes providing care to
people living with dementia. It included an integral (pub-
lished separately) cost-effectiveness analysis (Meads et al.,
2020) and process evaluation (Griffiths, Kelley, et al., 2019;
Surr, Griffiths, et al., 2019; Surr, Shoesmith, et al., 2019).
Follow up was at 6 and 16 months.
The trial originally had a closed-cohort design, following
all recruited residents in each care home from randomisa-
tion to final follow-up. However, there was unavoidably
high loss to follow-up, mainly due to death, impacting the
generalisability of the results to the intended population.
To enable the original research question to be robustly
addressed, in line with other examples (e.g. Underwood
et al., 2013), we recruited additional residents in each care
home at 16 months to allow a cross-sectional analysis at
baseline and 16 months to be performed as our primary
analysis. This also enabled us to assess the effects of the
intervention on all eligible and consenting residents resid-
ing in the care home during the intervention period and
not just those who had survived long enough to remain in
the care home at 16 months. For robustness, we undertook
sensitivity analyses on the original closed cohort.
Ethical issues
Ethical approval was granted by NRES Committee Yorkshire
& The Humber - Bradford Leeds REC ref 13/YH/0016. The
trial was registered with the International Standard
Randomised Controlled Trial Register (ISRCTN) reference
82288852. All study participants provided written
informed consent to take part. Where residents were
assessed as lacking capacity, in accordance with law
(Mental Capacity Act, 2005) a personal (family member
or friend) or nominated (staff member independent of
the research) consultee was appointed to provide advice
on their wishes.
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Study setting
To be eligible, care homes within three research recruit-
ment hub areas (West Yorkshire, London, Oxfordshire) were
required to: recruit a minimum of 10 residents with demen-
tia and agree to release staff for intervention implementa-
tion in compliance with the trial protocol. Care homes
were not eligible if: subject to care quality enforcement
notices or admission bans; had used DCM within the previ-
ous 18 months; or had recently, were currently, or were
planning to take part, in conflicting research.
All eligible care homes were approached (in random
order) in batches of 10–20 by postal invite, followed up by
researcher phone call, during which the trial was explained
in detail and additional eligibility screening was conducted.
A site visit, to discuss the trial with the manager, key
staff and the owner/owners representative (if applicable)
was arranged for homes expressing an interest. Where
care homes were part of a group the Head Office was
contacted concurrently to seek organisational support in
approaching homes and, where consented, to ensure
continued organisational support for participation. The
manager and owner were encouraged to discuss the trial
with the staff team to assess interest ahead of both pro-
viding written informed consent.
While this was a pragmatic trial, DCM use necessitates
staff have an understanding of PCC. Therefore, dementia
training was audited. Homes falling below a minimum
standard (training content and reach) received a half-day
dementia awareness and PCC training (Griffiths, Creese,
Garrod, Chenoweth, & Surr, 2018) delivered by experienced
trial facilitators, using materials adapted from those used
by a large UK care home provider. Staff responsible for
training within the care home was then able to cascade
the training to additional staff. The training provided
ensured all care homes had a minimum percentage of staff
trained in dementia and PCC awareness immediately prior
to randomisation.
Residents were recruited prior to care home randomisa-
tion (baseline) and also at 16-months post-randomisation.
Resident eligibility screening was undertaken by research-
ers with the care home manager or senior staff member.
All eligible residents within the care home at baseline and
16 months were approached. Baseline eligibility included
permanent residency, a dementia diagnosis or score 4 or
on the Functional Assessment Staging of Alzheimer’s
Disease (FAST) (Reisberg, 1988) and sufficient proficiency in
English, if self-consenting. Ineligibility included: terminal ill-
ness, permanent care in bed or participation in conflicting
research. At 16 months, additional eligibility criteria were
being resident in the care home for at least 3 months (to
permit a period of settling in and for potential effects of
any care home good practice related to intervention imple-
mentation to be realised) and not declining participation
at baseline.
Permanent members of staff who knew the resident
well, acted as proxy informants for data collection. Where
possible the same proxy informant was used when obtain-
ing individual resident data at each time point. Due to staff
turnover, annual leave and shift patterns, this was not
always possible.
Control
Routine care was delivered, with any changes recorded
(e.g. new staff roles, ownership, practice initiatives
or training).
Intervention
DCM was implemented pragmatically, using standard pro-
cedures (Bradford Dementia Group, 2005) and following
the most common UK implementation model of staff-led
use. Two staff members from each intervention care home
(‘mappers’) attended a standard four-day training in DCM,
including competency assessment, delivered by the
University of Bradford. Mapper eligibility included: being a
permanent staff member, having appropriate skills and
qualities and designated time to undertake DCM (assessed
by the home manager against a role descriptor, developed
by the trial team based on advice from DCM experts) (see
Figure 1) and willingness to undertake the role. Potential
mappers were also asked to complete a short, written
statement about their understanding of and desire to
undertake the mapper role. Written informed consent was
obtained from all mappers. Where a mapper withdrew dur-
ing the trial, another mapper was identified, consented and
trained, where possible.
DCM is described elsewhere (Brooker & Surr, 2006).
Briefly, it involves a five-phase cycle including holding
briefing session(s) for the staff team; observing up to five
residents with dementia for up to six consecutive hours;
undertaking data analysis; writing a report summarising the
data and providing feedback of findings to the staff team;
and action planning. During observations the mapper
records: resident behaviour every five-minutes through
choice of a Behaviour Category Code from a possible list of
23 codes; and accompanying Mood and Engagement Value
from a six-point scale (-5, 3, 1, þ1, þ3, þ5); and instan-
ces of good and poor staff care and communication with
residents in the form of Personal Enhancers and Detractors,
as and when they occur. The mapper also records qualita-
tive notes to supplement the coded data. To protect priv-
acy and dignity, observations only occur in communal
areas and not during provision of personal care. Since DCM
is implemented as a whole home intervention, mappers
and care home staff jointly selected residents to observe,
including residents not participating in the trial.
Mappers were asked to implement three DCM cycles,
scheduled 3-, 8- and 13-months post randomisation. To
support intervention implementation and consistency, a
number of measures was put in place. Mappers were pro-
vided with standardised templates based on DCM guide-
lines for completing each component of each cycle. While
mappers would usually undertake DCM without further
external input post-training, unless experienced mappers
are available within an organisation, additional methods of
support were put in place in this trial, taking into account
the pragmatic trial design. They included sending SMS
reminders ahead of each cycle and support from a DCM
expert during cycle one (see Surr, Shoesmith, et al., 2019).
Telephone and email support were provided thereafter,
if required.
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Figure 1. Mapper role descriptor.
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Adherence to intervention implementation (fidelity and
dose) was monitored through feedback from the external
experts, collection of standard DCM documentation from
mappers following each cycle (plus two additional docu-
ments relating recording attendance at briefing and feed-
back sessions) and telephone contact with mappers by trial
management staff. Only documented components/cycles
were recorded as completed. Intervention fidelity is
reported elsewhere (Surr, Griffiths, et al., 2019).
Randomisation and masking
Immediately following baseline data collection care homes
were randomised to intervention or control (3:2 ratio) using
24-hour, automated, computer generated randomisation
using minimisation. Arms were balanced for home/unit
type (general residential/nursing, specialist dementia care);
size (large  40 beds, medium/small < 40 beds); dementia
awareness training provision by the research team (yes,
no); and catchment area (West Yorkshire, London,
Oxfordshire). To maintain researcher blinding, randomisa-
tion and site notification were performed by the trial data
managers. Clusters were not blinded to allocation.
Sample size
Fifty care homes, each recruiting an average of 15 residents
provided 90% power at the 5% significance level to detect
a clinically important difference of 3 points on the Cohen-
Mansfield Agitation Inventory (Cohen-Mansfield, 1991)
(CMAI) (standard deviation (SD) 7.5 points), that is a moder-
ate standardised effect size of 04. Calculations assumed
25% loss to follow-up (Chenoweth et al., 2009) and an
inflation factor of 2.0 (i.e. cluster size of 11 analysable par-
ticipants at follow-up and an intracluster correlation coeffi-
cient (ICC) no greater than 0.1 (Fossey et al., 2006)). Due to
predicted sources of clustering (provision of care) and
higher predicted ICC in the intervention arm, an allocation
ratio of 3:2 was used, giving 30 (450) and 20 (300) care
homes (residents) in intervention and control, respectively.
Loss to follow-up was substantially higher than the
anticipated 25%, mainly due to resident deaths and to a
lesser extent, residents leaving the care home. To preserve
statistical power close to 90%, and the ability to detect a
standardised effect size of 0.4 SD, additional residents were
recruited at 16 months and a cross-sectional cohort ana-
lysis conducted, including all residents registered in the
study at 16 months (recruited at either baseline or
16 months).
Data collection
Data collection commenced in June 2014 and was com-
pleted in May 2017.
Resident and care home characteristics
These were completed via researcher interview with the
care home manager or other senior staff member.
Resident demographics and comorbidities collected via
interview and care records review.
Clinical Dementia Rating Scale (CDR) (Hughes, Berg,
Danziger, Coben, & Martin, 1982) rates dementia severity
across six-categories and provides an overall severity rating.
Functional Assessment Staging (FAST) (Reisberg, 1988)
records the functional severity of dementia, ranging from 1
(no dementia) to 7 (severe dementia).
Care Home Demographics including home (size, type,
ownership, staff turnover, staff ratios, etc.) and manager
(qualifications, length of time in post, etc.) information.
Outcome measures
Outcome measures were completed by researcher (blinded
to intervention allocation) via interview with staff proxy
informant, at baseline, 6 and 16 months, unless other-
wise stated. Mappers were not permitted to be
proxy informants.
Primary outcome
CMAI (Cohen-Mansfield, 1991) measures the frequency of
29 agitated behaviours on a seven-point scale, reported for
the previous two-weeks providing a total score
(range 29–203).
Secondary outcomes
Neuropsychiatric Inventory - Nursing Home (NPI-NH):
(Cummings et al., 1994) 12-item measure of the frequency,
severity and disruptiveness of neuropsychiatric symptoms
(e.g. delusions, hallucinations, apathy) in care home
populations.
DEMQoL-Proxy: (Smith et al., 2007) 32-item, dementia-
specific, proxy quality of life questionnaire, modelled to
enable the derivation of preference-based indices (utility
values), the latter of which were employed in the second-
ary cost-utility analyses (Rowen et al., 2012).
EQ-5D-5L/EQ-5D-5L Proxy: (EuroQol Group, 1990) five-
item measure of health outcome, providing a single index
value for health status, including self-report and proxy ver-
sions (Herdman et al., 2011).
Quality of Life in Late Stage Dementia (QUALID): (Weiner
et al., 2000) 11-item dementia specific proxy measure of
quality of life rating the presence and frequency of QoL
indicators over the previous seven days.
QOL-AD (care home): (Edelman, Fulton, Kuhn, & Chang,
2005) 15-item self-report measure of quality of life with
adapted wording relevant to those living in long-term care
and reported to be reliable in use with people with mild to
severe dementia (Hoe, Katona, Roch, & Livingston, 2005).
Quality of Interactions Schedule (QUIS): (Dean, Proudfoot,
& Lindesay, 1993) observational measure of the quality and
quantity of staff interactions with residents, Researchers
observed using 15-minute time-sampling over two, one-
hour observation periods, on different days (one AM and
one PM) within a week, during a period of activity. The
proportion of positive to other interactions was compared.
Prescription Medications: within categories of interest
(antipsychotic, benzodiazepine, non-benzodiazepine anxio-
lytic, Memantine, analgesic, anti-depressant) and adminis-
tration of these (regular/as required (PRN)), via researcher
review of the previous month’s medication records.
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Sense of Competence in Dementia Care Staff (SCIDS):
(Schepers, Orrell, Shanahan, & Spector, 2012) a 17-item
scale measuring staff members’ feelings of competence in
caring for people with dementia. It was not possible to
analyse data from this measure due to poor return rates.
General Health Questionnaire (12-item) (GHQ-12):
(Goldberg & Williams, 1988) a measure of stress/psycho-
logical well-being, used to assess staff work stress. Due to
poor return rates, collection of this measure was ceased to
support improved return rates of the SCIDS.
Supportive outcome data
As the primary outcome, data were provided by an un-
blinded staff proxy, an independent researcher collected
additional observational agitation data.
Cohen Mansfield Agitation Inventory - Observational
(CMAI-O): (Griffiths, Albertyn, et al., 2019) an observational
version of the CMAI, developed for use in this trial, col-
lected on a single day (approx. 10:00–12:00 and
14:00–17:00) in communal areas.
Pittsburgh Agitation Scale (PAS): (Rosen et al., 1994)
observational rating of agitation severity, collected in com-
munal areas on a single day (approx. 10:00–12:00
and 14:00–17:00).
Cost-effectiveness analysis
Cost per unit of improvement in CMAI at 16 months and
cost per QALY for residents recruited at baseline (i.e. closed
cohort) using a health and personal social service provider
perspective. Unit costs for health service staff and resources
were obtained from national sources. Costs of the DCM
intervention consisted of two components: (i) delivery and
receipt of DCM training; and (ii) implementation of the
DCM process in care homes. Discounting at the NICE pre-
ferred rate of 3.5% per annum for costs and effects were
conducted for values post 12 months.
Missing data
Where there were no instructions by instrument authors on
how to handle missing data items, prorating was used if
25% of items were missing, otherwise scores were
assigned as missing. Complete cases analysis was the
primary method for handling missing scale data in the
cross-sectional analyses of primary, secondary and health
economic outcomes, under the assumption that data are
missing completely at random (MCAR). If data were not
MCAR and predictors were identified, then analyses used
multiple-imputed data, assuming that cross-sectional data
were missing at random (MAR), and complete cases were
reported as a sensitivity analysis.
Data analysis
A comprehensive Statistical and Health Economic Analysis
Plan was developed and approved a priori. All analyses
were performed in SAS software v9.4 (SAS Institute, Cary,
NC) or Stata v14 (StataCorp, College Station, TX).
The continuous primary outcome of agitation (CMAI
score) was analysed on an intention-to-treat (ITT) basis on
the cross-sectional sample using a linear two-level hetero-
scedastic regression model that allowed the cluster and
resident-level random effects to vary by arm. The model
adjusted for minimisation factors (care home type, size,
provision of dementia awareness training and recruiting
hub) and average care home-level baseline characteristics
(dementia severity via CDR, age and CMAI score) as
fixed effects.
The robustness of the primary effectiveness analysis to
the choice of covariates, the outcome measure and the
sample was assessed via sensitivity analyses. The primary
effectiveness analysis was repeated using the CMAI-O and
PAS scores in place of the CMAI, using the closed-cohort
sample, and including dementia severity, age and CMAI
score as covariates at the resident-level.
An exploratory analysis of the effect of the intervention
received (as opposed to what was intended) was under-
taken using complier average causal effect (CACE) analyses
(Angrist, Imbens, & Rubin, 1996) of the cross-sectional sam-
ple, via two-stage least square instrumental variable regres-
sions, using robust standard errors to allow for clustering.
In this analysis, compliers were defined as care homes that
completed at least one cycle to an acceptable level. Thus,
our CACE analysis estimated the effect of receiving at least
one DCM cycle.
For secondary outcomes (behaviours staff find challeng-
ing, mood, resident quality of life, and the quality of staff/
resident interactions), analyses were performed for the
cross-sectional sample at 16 months and closed-cohort at 6
months and 16 months. Analyses were undertaken using
the same principles as the primary analysis and the same
covariates (for closed-cohort analyses, individual resident-
level covariates were used as appropriate). Cluster-specific
linear two-level heteroscedastic regressions were fitted
where outcomes were continuous.
Cost-effectiveness analysis measured incremental costs,
CMAI and QALYs for residents recruited at baseline (i.e.
closed cohort, n¼ 726) using Seemingly Unrelated
Regression (SUR) (Willan, Briggs, & Hoch, 2004), a system of
regression equations that recognises individual costs and
outcomes are correlated.
Results
Demographics
Across the 50 care homes, 726 residents were registered at
randomisation. Loss to follow-up at 16 months in the ori-
ginal cohort was 312/726 (43.0%), with the majority 272/
312 (87.2%) due to deaths. Participant loss to follow-up
was comparable to other recently reporting care home tri-
als (e.g. Ballard et al. (2018) 35% loss to follow-up at 9
months; Livingston et al. (2019) 21% at 8 months and
Sackley et al. (2015) 30% at 12 months). At 16 months, 261
additional residents were recruited (99 control, 162 inter-
vention), totalling 675 residents included in the primary
analysis (see Figure 2).
Care home and resident characteristics are presented in
Tables 1 and 2, respectively.
Intervention fidelity was sub-optimal compared to
protocol; 7/31 (22.6%) intervention care homes did not
complete a full intervention cycle to an acceptable level,
16/31 (51.6%) completed one cycle, 4/31 (12.9%)
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completed two cycles and only 4/31 (12.9%) completed all
three cycles (Surr, Shoesmith, et al., 2019). Likewise, moni-
toring indicated that there was poor consistency in the
fidelity, dose and reach of DCM implementation in terms of
the execution of components of each cycle (briefing, map-
ping, analysis, feedback and reporting, action planning).
Mapper retention over the trial period was problematic
with one or both mappers withdrawing from their role
(mainly due to leaving the organisation or long-term
absence [sickness/maternity]) in 54.8% of homes (Surr,
Griffiths, et al., 2019). The process evaluation identified a
range of barriers and facilitators to implementation of DCM
at a mapper, care home, intervention and trial level
(Griffiths, Kelley, et al., 2019). While mappers and managers
Figure 2. Care home and resident CONSORT diagram.
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could identify a range of ways in which they felt using
DCM had led to positive changes in practice, overall homes
reported a lack of time, resources, skills and confidence to
implement DCM sustainably. The external experts were val-
ued and many homes reported being unable to continue
using DCM without the external input (Surr, Shoesmith,
et al., 2019). In-depth discussion of intervention fidelity,
barriers and facilitators to implementation and the role of
external experts in supporting implementation can be
found in the separate papers on these topics (as
cited above).
Primary analysis
Analyses on the cross-sectional sample (primary) and the
closed-cohort (see Table 3) identified no significant differ-
ence in mean agitation scores (CMAI) between arms at 16
months. The mean difference in total CMAI score from the
two-level heteroscedastic linear regression model fitted to
the multiply-imputed data (assuming data were MAR) was
–2.11 points in intervention vs control (adjusted means
45.47 points in control; 43.35 points in intervention, 95% CI
–4.66 to 0.44, p¼ 0.104). The unadjusted ICC was zero in
the control and 0.058 in the intervention arm, but the
adjusted ICC was zero in the control and 0.001 in the inter-
vention arm, indicating that intervention arm between-clus-
ter heterogeneity was explained by model covariates.
Using the complete cases, the mean difference was –2.19
points for intervention versus control (95% CI –4.81 to
0.43) and the adjusted ICC was zero in both treatment
arms, indicating the treatment effect was neither clinically
meaningful nor statistically significant (p¼ 0.099).
Analyses of the secondary outcomes
Analyses of NPI-NH, quality of life and quality of staff inter-
actions on the closed-cohort at 6 months and on the cross-
sectional sample and the closed-cohort at 16 months (see
Supporting Information S4) showed no benefits of interven-
tion over control.
At baseline, the proportions of residents recorded with
behaviours reported on the NPI-NH were similar across the
intervention and control arms (see Supporting Information
S3). However, the average NPI-NH score was higher in the
control arm. At 16 months, the proportion of residents
experiencing one or more behaviours was smaller in the
intervention arm compared to control for both the cross-
sectional and closed-cohort samples. There were no signifi-
cant differences between the arms at 6 or 16 months, with
greater average NPI-NH score reductions in the con-
trol arm.
There were poor self and family carer proxy completion
rates of the QOL-AD and QUALID respectively (see
Supporting Information S3). No statistically significant dif-
ferences were found in staff proxy QUALID scores, relative
proxy QUALID or resident rated QOL-AD at baseline, 6 or
16 months in either sample.
The proportion of positive interactions as measured by
the QUIS (see Supporting Information S3) differed between
arms at baseline and at 6 months, with a higher proportion
of positive interactions in the intervention group. These did
not differ significantly by treatment arm at 16 months.
There were no clinically meaningful or statistically sig-
nificant differences in PRN use of medications at 6 or 16
months (see Supporting Information S4), although PRN
medication administration rates were low across both arms
Table 1. Baseline care home demographics.
Characteristics Control (n¼ 19) Intervention (n¼ 31)
Unit type (N (%) missing)
– General residential/nursing home
11 (57.9%) 0 20 (64.5%) 0
– Specialist dementia care home/unit 8 (42.1%) 0 11 (35.5%) 0
More than one unit included in study (N (%) missing) 3 (15.8%) 0 3 (9.7%) 0
DCM used within last 18-months to 5 years (N (%) missing) 11 (57.9%) 0 20 (64.5%) 0
Residents’ meeting held within the last 6 months (N (%) missing) 17 (89.5%) 0 30 (100%) 1
Relatives’ meeting held within the last 6 months (N (%) missing) 18 (94.7%) 0 29 (96.7%) 1
Number of beds in the care home (Mean (SD) missing) 28.8 (8.97) 2 36.8 (14.28) 1
Number of permanent residents (Mean (SD) missing) 30 (11.27) 0 32.9 (14.02) 1
Percentage of permanent residents with dementia (Mean (SD) missing) 83.1 (21.21) 0 74.2 (22.48) 1
Percentage of self-funded residents (Mean (SD) missing) 52.8 (28.12) 0 37.9 (21.12) 1
Cost of a self-funded place per year (£) (Mean (SD) missing) 44,553 (13,291) 0 41,638 (13,003) 1
Resident:staff ratio daytime (Median (Q1, Q3) Missing) 5.2 (3.8, 6.3) 0 4.7 (3.9, 6.4) 1
Resident:staff ratio night time (Median (Q1, Q3) Missing) 9.5 (7.5, 11.7) 0 9.7 (7.8, 11.6) 1
Table 2. Resident demographics.
Closed cohort at baseline Cross-section at 16 months
Resident characteristics Control (n¼ 308) Intervention (n¼ 418) Control (n¼ 287) Intervention (n¼ 388)
Age at randomisation Years (Mean (SD)) 85.3 (7.38) 86 (7.83) 83.7 (7.77) 85.2 (7.79)
Gender: Male N (%) 64 (20.8%) 126 (30.1%) 71 (24.7%) 110 (28.4%)
Number of comorbidities per resident (Median (Q1, Q3)) 2 (1, 4) 2 (1, 4) 2 (1, 3) 3 (1, 4)
Selected comorbidities a Anxiety 34 (11.0%) 23 (5.5%) 26 (9.1%) 27 (7.0%)
Depression 62 (20.1%) 55 (13.2%) 64 (22.3%) 66 (17.0%)
Psychosis 16 (5.2%) 24 (5.7%) 11 (3.8%) 21 (5.4%)
Sleep disturbance 6 (1.9%) 7 (1.7%) 2 (0.7%) 5 (1.3%)
Delirium 3 (1.0%) 2 (0.5%) 2 (0.7%) 2 (0.5%)
FAST dementia stage (out of completed scores) N (%) (n¼ 306) (n¼ 391) (n¼ 284) (n¼ 384)
No/early (score 1, 2, 3) 5 (1.7%) 1 (0.3%)
Mild (score 4) 39 (12.7%) 56 (14.3%) 22 (7.7%) 35 (9.1%)
Moderate (score 5) 26 (8.5%) 48 (12.3%) 20 (7.0%) 21 (5.5%)
Moderately severe (score 6) 166 (54.2%) 214 (54.7%) 168 (59.2%) 238 (62.0%)
Severe (score 7) 70 (22.9%) 72 (18.4%) 74 (26.1%) 90 (23.4%)
aNot mutually exclusive.
8 C. A. SURR ET AL.
Table 3. Primary, sensitivity and health economic analyses assuming missing data are MAR.
Analysis
Adjusted mean
in control
Adjusted mean in
intervention
Estimated
mean difference
Lower 95%
confidence limit
Upper 95%
confidence limit p-value
Adjusted ICC for
intervention
Adjusted ICC
for control N
Primary analysis 45.47 43.35 –2.11 –4.66 0.44 0.104 0.001 0.000 675
Sensitivity analyses (cross-
sectional sample)
Key sensitivity analysis (hub
omitted from the model)
46.02 43.78 –2.24 4.91 0.42 0.099 0.010 675
1. Adjusting for before-after
eligibility changea
44.82 42.69 –2.13 –4.71 0.45 0.105 0.002 0.000 675
2. Care home size as a
continuous variable
45.59 43.21 –2.38 –5.00 0.25 0.076 0.000 0.000 675
3. Homogeneous clustering
across arms
45.41 43.32 –2.09 461 0.44 0.105 0.001 675
4a. CMAI-O (AM) 31.00 30.41 –0.58 –1.62 0.45 0.269 0.215 0.006 675
4b. CMAI on subset with CMAI-
O (AM)
47.49 43.43 –4.06 –7.55 –0.57 0.023 0.016 0.001 365
4c. CMAI-O (PM) 31.34 31.11 –0.22 –1.52 1.08 0.737 0.220 0.013 675
4d. CMAI on subset with CMAI-
O (PM)
47.49 43.43 –4.06 –7.55 –0.57 0.023 0.016 0.001 365
4e. PAS (AM) 0.93 0.73 –0.20 –0.67 0.27 0.402 0.166 0.011 675
4f. CMAI on subset with PAS (AM) 47.49 43.43 –4.06 –7.55 –0.57 0.023 0.016 0.001 365
4g. PAS (PM) 1.17 0.89 –0.28 –0.96 0.41 0.429 0.299 0.018 675
4h. CMAI on subset with PAS (PM) 47.49 43.43 –4.06 –7.55 –0.57 0.023 0.016 0.001 365
5. CMAI at 16 months
(closed-cohort)
46.4 43.16 –3.25 –6.13 –0.37 0.027 0.013 0.001 726
Cost-effectiveness analyses
(closed-cohort sample)
Mean costs in control Mean costs in
intervention
Adjusted mean
difference
Mean outcome
in control
Mean outcome in
intervention
Adjusted mean
difference
Incremental cost
effectiveness ratio
N
EQ-5D-5L £2060 £3539 £1479 0.708 0.718 0.024 £60,627 726
CMAI £2345 £3318 £974 –0.557 –1.767 –3.37 £288.88 404
aEligibility changed in December 2014 after first two care homes randomised.
CMAI-O¼ Cohen Mansfield Agitation Inventory – Observational; PAS¼ Pittsburgh Agitation Scale; CMAI¼ Cohen Mansfield Agitation Inventory; EQ-5D-5L ¼ 5 item measure of health status.
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at all time-points, with wide confidence intervals making
the results difficult to interpret (Surr et al., in press).
Supportive, sensitivity and CACE analyses
For supportive analyses (see Table 4), the overall CMAI-O
and PAS scores were lower than the proxy reported scores
(see Supporting Information S1), indicating a potential
over-estimation of the treatment effect within the primary
analysis. The mean differences between control and inter-
vention groups were smaller using CMAI-O independent
observations. Supportive analyses of the closed-cohort at 6
and 16 months indicated no differences in CMAI, CMAI-O
or PAS scores at 6 months, and no differences in CMAI-O
and PAS scores at 16 months, confirming that there was
no evidence that the intervention was superior to control.
Sensitivity analyses conducted on the cross-sectional
sample supported the findings of the primary ITT analysis.
No statistically significant or clinically meaningful differen-
ces were found between the arms (see Table 4). The sensi-
tivity analysis conducted on the closed-cohort gave a mean
difference of –3.25 (95% CI –6.13 to –0.37, p¼ 0.027).
A CACE analysis of the cross-sectional sample, gave a
mean difference in CMAI score at 16 months of –2.5 points
(95% CI –5.4 to 0.4, p¼ 0.089) lower in ‘compliers’ com-
pared to ‘non-compliers’ (see Table 3 and Supporting
Information S2), indicating that the intention to treat esti-
mate from the primary analysis was comparable to being a
complier (completing at least one cycle to an accept-
able level).
Analyses of safety
There were no reported unexpected serious adverse events.
There were 272 (37.5%) reported deaths amongst residents
comprising the original cohort (111/308 (36.0%) control
and 161/418 (38.5%) intervention) (Surr et al., 2020). Most
residents in the closed-cohort did not have any hospital
admissions (231/308 (75.0%) control and 308/418 (73.7%)
intervention).
Economic analysis
This is reported in detail elsewhere (Meads et al., 2020). In
summary, the total cost of DCM was estimated to be
£421.07 per resident (£9,290.30 per care home). Control
arm intervention costs were assumed to be zero. Using the
multiple-imputed data, assuming the cross-sectional data
are MAR, incremental cost per unit improvement in CMAI
and QALYs was £289 and £60,627, respectively, for inter-
vention versus control (see Table 3).
Discussion and implications
This is the only pragmatic trial to be conducted of DCM
internationally. It has permitted assessment of whether the
promising results of efficacy trials translate into application
of DCM in a real-world context, using a sample that is gen-
eralisable to the wider care home population. In this real-
world context, DCM was not found to be effective versus
control on the primary or any secondary outcomes, nor
was it cost-effective. Sensitivity analysis gave a mean differ-
ence apparently contradicting the primary analysis conclu-
sion. However, due to loss to follow-up and missing data,
they rely on multiple imputed data for a large percentage
of participants and thus are not reliable. The exploratory
CACE analyses suggested a dose-response relationship,
however, further research is required to explore this, par-
ticularly given so few care homes implemented more than
one DCM cycle, meaning the results are difficult to inter-
pret reliably. The study results may be explained by lower
than expected intervention compliance, with only 8/31
(25.8%) completing more than the first external expert
mapper supported DCM cycle (Surr, Griffiths, et al., 2019).
The cost per unit improvement in CMAI was higher than
other recent evaluations of interventions involving staff
training in PCC or communication skills with or without
behavioural management training (£6 to £62, 2011 UK pri-
ces) (Livingston, Barber, et al., 2014). The cost per QALY
was also higher than the upper bound of the threshold
over which treatments are least likely to be funded in
Table 4. Supportive analyses assuming missing data are MAR.
Analysis
Adjusted mean
in control
Adjusted mean
in intervention
Estimated
mean difference
Lower 95%
confidence limit
Upper 95%
confidence limit p-value
Adjusted ICC for
intervention
Adjusted ICC
for control N
Supportive analyses
(closed-cohort
sample),
multiple
imputation
6 -months 726
CMAI 43.44 44.04 0.59 –1.98 3.17 0.653 0.049 0.001
CMAI-O (AM) 31.40 31.86 0.46 –0.37 1.30 0.276 0.019 0.000
CMAI-O (PM) 31.64 32.20 0.57 –0.27 1.40 0.182 0.023 0.001
PAS (AM) 1.04 1.18 0.14 –0.24 0.52 0.473 0.022 0.001
PAS (PM) 1.05 1.23 0.18 –0.20 0.57 0.350 0.021 0.001
16 months
CMAI-O (AM) 30.90 30.50 –0.40 –1.27 0.46 0.361 0.014 0.001
CMAI-O (PM) 31.17 31.05 –0.13 –1.09 0.84 0.795 0.012 0.001
PAS (AM) 0.91 0.79 –0.12 –0.52 0.28 0.547 0.008 0.001
PAS (PM) 1.08 0.91 –0.17 –0.67 0.33 0.502 0.018 0.001
CACE analyses,
multiple
imputation
Treatment effect (SE)
At least one cycle to
an acceptable level
–2.5 (1.5) –5.4 0.4 0.089
CMAI-O¼ Cohen Mansfield Agitation Inventory – Observational; PAS¼ Pittsburgh Agitation Scale; CMAI¼ Cohen Mansfield Agitation Inventory;
CACE¼ Complier Average Causal Effect.
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England, although some lower estimates were reported in
sensitivity analyses (Meads et al., 2020). The findings align
with one (Chenoweth et al., 2009) and contrast with
another previous, non-UK, cost analysis of DCM (van de
Ven et al., 2014). Compared to other recent UK trials of
interventions aimed to reduce agitation in care home resi-
dents, DCM compares unfavourably (e.g. Ballard et al.,
2018; Livingston et al., 2019) in terms of both effectiveness
and cost-effectiveness of the interventions tested.
While retaining DCM use as close to real world practice
as possible, we included a range of additional supports to
optimise implementation, which could feasibly (and poten-
tially affordably) be implemented in real-world practice
(e.g. mapper selection, external expert support, ongoing
telephone/email support, provision of standardised docu-
mentation and SMS reminders). Nevertheless, considerable
DCM implementation challenges still occurred (Griffiths,
Kelley, et al., 2019). Consequently, caution is needed in
comparing these outcomes with previous DCM trial find-
ings which did not utilise a pragmatic design. The current
findings contrast with two previous explanatory trials,
(Chenoweth et al., 2009; Rokstad et al., 2013) which found
significant benefits of DCM for resident outcomes, but
which adopted ideal case, non-standard, researcher-led
DCM cycles. Our results concur with those of other studies
using real-world, care home staff-led DCM cycles, but
which did not utilise effectiveness trial designs (Dichter
et al., 2015; van de Ven et al., 2013).
Robust research evidence on models of DCM implemen-
tation is limited, although staff-led implementation is
reported to be challenging (Surr, Griffiths, & Kelley, 2018).
In this trial, the greatest perceived barriers and facilitators
to DCM implementation were at the mapper and care
home levels (Griffiths, Kelley, et al., 2019), including lack of
mapper time, skills and confidence to implement DCM and
lack of resources and management support. It is possible
additional training alongside ongoing, rather than time-lim-
ited support from an external expert might address mapper
barriers. However, provision of additional training did not,
improve DCM implementation or outcomes in an RCT
where mappers also received three-day ‘Advanced User’
training (van de Ven et al., 2013). Lack of resources and
management support was despite detailed discussions at
care home recruitment about what trial involvement and
DCM implementation would involve. However, there were
manager changes in 42% of recruited homes over the trial
period, (Surr et al., in press) which may account for some
of the challenges in sustaining high level support for DCM
over 16 months. Thus, even with additional information,
screening and support to that which is provided as stand-
ard, many care homes appear to lack the financial, and
human resources to successfully and sustainably implement
DCM.
Rapaport, Livingston, Murray, Mulla, and Cooper (2017)
identify a number of components that can support success-
ful implementation of interventions in care home settings,
these include interactive training, post-training support,
retaining written materials post-training, aiming to train
most staff and building interventions into routine care.
DCM as implemented in this trial included all of these com-
ponents with the exception of training most staff, which
would not be feasible given the costs and complexity of
the method and building the intervention into routine
care. Our results indicate that embedding DCM within rou-
tine practice is challenging for many homes due to its
complexity, time consuming nature and resource intensity.
Therefore, the standard model of DCM implementation
may not be fit for purpose in the majority of care home
settings, without the provision of additional ongoing exter-
nal support or an alternative external model of implemen-
tation. Alternative interventions for reducing agitation
should be explored, which make careful consideration of
the learning from this trial and the growing evidence-base
on intervention implementation in care home settings.
Strengths and limitations
This is the largest and only definitive, pragmatic RCT world-
wide of the effectiveness of DCM, in care home settings
using real-world, routine practice conditions. Limitations
include relying on unblinded staff proxy reports for primary
and secondary outcome measure completion, owing to
self-report difficulties for some participants with dementia.
Blinded observational measures were also performed but
these were limited by the proportion of missing values.
Due to the large loss to follow up rates, there was consid-
erable missing data to manage within the health economic
analyses. The random selection of care homes ensured
good representation and thus promoted generalisability of
the trial in the UK. Exclusion of care homes that were
subject to care quality admissions bans or other improve-
ment measures, means poorly performing homes were
not represented. While staff blinding to treatment alloca-
tion was not possible, researcher blinding was maintained
throughout. Observational measures of agitation completed
by a blinded researcher were used to detect any potential
reporting bias. The fact observations of agitation did not
include personal care is a limitation, since personal care is
a time when agitation is likely to occur or be triggered.
Given only DCM cycles where documentation had
been received to evidence completion were recorded as
completed, we may have under-reported actual
implementation.
Conclusion and implications
This trial suggests that in the majority of UK care home set-
tings using routine staff-led implementation, may not pro-
vide the right conditions for a complex system-level
intervention like DCM. The similar findings in other trials
that used staff-led implementation of DCM, suggests this is
likely to be the case internationally. Either alternative inter-
ventions for addressing agitation in care home residents
with dementia should be sought, or consideration needs to
be given to different models that may optimise DCM
implementation. The results have implications for the
design and implementation of complex interventions in
care homes more widely.
The views and opinions expressed therein are those of
the authors and do not necessarily reflect those of the
HTA, NIHR, NHS or the Department of Health and
Social Care.
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